Company intelligence / Profile preview

Osteros

Ownership: Private
Development stage: Preclinical

Overview

Osteros Biomedica completed a Phase 1 clinical trial for MBC-11, demonstrating safety and preliminary efficacy in reducing metabolic activity of bone lesions in patients with advanced cancers. The therapy showed a favorable safety profile and significant reduction in lesion activity at tolerable doses. Further clinical development was planned following these results.

Therapeutic areas: Oncology
Modalities: Small moleculeSynthetic chemical conjugateBisphosphonate-drug conjugate
Industry: Biotech

Partnerships

MBC Pharma Inc. – technology originator and collaboratorRussian Venture Company – investor/funding support through Maxwell fund

Beyond the preview

Go deeper on Osteros.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Osteros.

Explore the full profile